DUBLIN--(BUSINESS WIRE)--The "Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 Update" report has been added to ResearchAndMarkets.com's offering.
This report gives an important update to the previous year with an expert analysis on how COVID-19 is impacting clinical trials and the potential move toward decentralized clinical trials. Findings are based on a survey conducted with 154 respondents from around the world that belonged to Pharma/Biotech, Government/Academic Institutions, CROs, CMOs, or other contract service providers.
The report includes
- Study Design and Key Findings.
- Primary Concerns, which include business concerns, clinical trial concerns for decentralized clinical trials and addressing trial disruption.
- Movement Toward Decentralized Trials, including pre and post pandemic decentralized clinical trials use, future movement toward using decentralized clinical trials and cost comparison.
- Challenges Facing Decentralized Trials, which explores the biggest challenges, changes, considerations and risk deviations for decentralized clinical trials.
Scope
- A total of 154 The Publisher Pharma clients and prospects from the around the world participated in the seven-minute survey, which was fielded from August 3, 2021 to September 2, 2021.
- This report includes and is based around industry opinions on COVID-19's impact on clinical trials and the use of decentralized clinical trials.
Key Topics Covered:
1 Study Design
1.1 Background
1.2 Objectives and Design
1.3 Respondent Mix
1.4 Respondent Profiles
2 Key Findings
3 Primary Business and Clinical Trial Concerns
3.1 Primary Business Concerns
3.2 Primary Clinical Trial Concerns
3.3 Clinical Trial Disruptions
3.4 Addressing Clinical Trial Disruptions
4 Movement Toward Decentralized Trials
3.1 Pre-pandemic Decentralized Trials Use
3.2 Post-pandemic Decentralized Trials Use
3.3 Future Movement Toward Decentralized Clinical Trial Use
3.4 Cost Comparison
4 Challenges Facing Decentralized Trials
4.1 Biggest Challenges
4.2 Biggest Changes
4.3 Biggest Considerations
4.4 Risk Deviations
5 Summary
For more information about this report visit https://www.researchandmarkets.com/r/jnulsb
